The new treatment strategy for pulmonary arterial hypertension
Yuichi Tamuraa,b Keiichi Fukudaa
aDepartment of Cardiology, Keio University School of Medicine
bCentre National de Référence de l'Hypertension Pulmonaire Sévère, Université de Paris
Because of specific treatment options, such as epoprostenol infusion therapy, the prognosis of pulmonary arterial hypertension (PAH) has dramatically improved. Compared with prognoses reported from Western countries, those in Japanese centers for PAH are better because Japanese specialists perform advanced therapies and make treatment goals that are not exercise tolerance, but pulmonary artery pressure. The research from multi-Japanese PAH centers revealed that patients achieving mean pulmonary artery pressure of less than 44.5 mmHg had good prognosis. This result suggests that advanced multiple drug treatment containing epoprostenol without hesitation improves prognosis.
Epoprostenol Pulmonary artery pressure Exercise tolerance Treatment goal
AJRS, 3(4): 486-491, 2014